Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study will enrol patients with diabetes who have already elected to undergo pars plana
vitrectomy (eye surgery) to remove persistent vitreous haemorrhage (a complication of severe
diabetic eye disease in which blood fills the inner cavity of the eye, obscuring the vision
and preventing treatment to stop the bleeding). Those in the treatment arm will have an
intravitreal injection of ranibizumab (Lucentis) at the same dose used for the treatment of
neovascular (wet) age-related macular degeneration (a disease that has some features in
common with diabetic eye disease).
It is hypothesised that this will promote clearance of the vitreous haemorrhage and that
this, in turn, may mean that some patients do not need to proceed to vitrectomy.